Risk factors for serious adverse events related to vitamin K antagonists in children with congenital or acquired heart disease: a prospective cohort study.


Journal

Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377

Informations de publication

Date de publication:
12 2023
Historique:
received: 29 05 2023
revised: 23 10 2023
accepted: 25 10 2023
medline: 27 11 2023
pubmed: 18 11 2023
entrez: 17 11 2023
Statut: ppublish

Résumé

To assess the occurrence of thrombosis and major bleeding in children with congenital or acquired heart disease (CAHD) treated with VKA and to identify risk factors for these serious adverse events (SAE). All children enrolled in our VKA dedicated educational program between 2008 and 2022 were prospectively included. The time in therapeutic range (TTR) was calculated to evaluate the stability of anticoagulation. Statistical analysis included Cox proportional hazard models. We included 405 patients. Median follow-up was 18.7 (9.3-49.4) months. The median TTR was 83.1 % (74.4 %-95.3 %). No deaths occurred because of bleeding or thrombotic events. The incidences of thrombotic and major bleeding events were 0.9 % (CI95 % [0.1-1.8]) and 2.3 % (CI95 % [0.9-3.8]) per patient year, respectively. At 1 and 5 years, 98.3 % (CI95 % [96.2 %-99.2 %]) and 88.7 % (CI95 % [81.9 % 93.1 %]) of patients were free of any SAE, respectively. Although the mechanical mitral valve (MMV) was associated to major bleeding events (HR = 3.1 CI95 % [1.2-8.2], p = 0.02) in univariate analysis, only recurrent minor bleeding events (HR = 4.3 CI95 % [1.6-11.7], p < 0.01) and global TTR under 70 % (HR = 4.7 CI95 % [1.5-15.1], p < 0.01) were independent risk factors in multivariable analysis. In multivariable analysis, giant coronary aneurysms after Kawasaki disease (HR = 7.8 [1.9-32.0], p = 0.005) was the only risk factor for thrombotic events. Overall, VKA therapy appears to be safe in children with CAHD. Suboptimal TTR, regardless of the indication for VKA initiation, was associated with bleeding events.

Identifiants

pubmed: 37976734
pii: S0049-3848(23)00302-X
doi: 10.1016/j.thromres.2023.10.017
pii:
doi:

Substances chimiques

Anticoagulants 0
Fibrinolytic Agents 0
Vitamin K 12001-79-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

93-103

Informations de copyright

Copyright © 2023. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Fanny Bajolle (F)

M3C-Paediatric Cardiology center, Hôpital universitaire Necker Enfants-malades, AP-HP, Université de Paris, Paris, France.

Neil Derridj (N)

M3C-Paediatric Cardiology center, Hôpital universitaire Necker Enfants-malades, AP-HP, Université de Paris, Paris, France. Electronic address: neil.derridj@aphp.fr.

Joan Bitan (J)

Hematology Laboratory, Hôpital universitaire Necker Enfants-Malades, AP-HP, Université de Paris, Paris, France.

Aurelie Grazioli (A)

M3C-Paediatric Cardiology center, Hôpital universitaire Necker Enfants-malades, AP-HP, Université de Paris, Paris, France.

Nicolas Pallet (N)

Department of Clinical Chemistry, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris, France.

Dominique Lasne (D)

Hematology Laboratory, Hôpital universitaire Necker Enfants-Malades, AP-HP, Université de Paris, Paris, France.

Damien Bonnet (D)

M3C-Paediatric Cardiology center, Hôpital universitaire Necker Enfants-malades, AP-HP, Université de Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH